FIRST-LINE

作品数：102被引量：297H指数：9
导出分析报告
相关领域：医药卫生更多>>
相关作者：杨天赐更多>>
相关机构：南京大学医学院附属鼓楼医院湖南省肿瘤医院北京肿瘤医院厦门大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金高等学校学科创新引智计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers:Feasible or not feasible?
《World Journal of Gastroenterology》2025年第10期134-138,共5页Jian-Qiang Chen Xiang Lan 
A clinical trial of nab-paclitaxel plus capecitabine as a first-line treatment for advanced biliary tract cancers was conducted.We analyzed the development of systemic therapy recommended by the National Comprehensive...
关键词：NAB-PACLITAXEL CAPECITABINE Biliary tract cancers Systemic therapy Firstline regimen 
Addition of SHR-1701 to first-line capecitabine and oxaliplatin(XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
《Signal Transduction and Targeted Therapy》2025年第1期340-349,共10页Miao-Zhen Qiu Yuxian Bai Jufeng Wang Kangsheng Gu Mudan Yang Yifu He Cheng Yi Yongdong Jin Bo Liu Feng Wang Yu-kun Chen Wei Dai Yingyi Jiang Chuanpei Huang Rui-Hua Xu Hui-Yan Luo 
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
关键词：BEVACIZUMAB colorectal SHR 
First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma:a multi-center phase 2 study被引量：1
《Signal Transduction and Targeted Therapy》2024年第12期5664-5670,共7页Ning Li Jin Xia Xiaohui Gao Jianwei Zhou Yonggui Hong Donghai Cui Xuesong Zhao Tao Wu Yanzhen Guo Junsheng Wang Suxia Luo 
Henan Province Health Science and Technology Innovation Young and Middle-Aged Leader Project(YXKC2021008).
Although first-line immunochemotherapy has improved prognosis for patients with advanced esophageal squamous cell carcinoma(ESCC),more effective strategies still require further investigation.This multi-center,phase I...
关键词：ESOPHAGEAL CHEMOTHERAPY METASTATIC 
Next-generation aluminum adjuvants:Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs
《Acta Pharmaceutica Sinica B》2024年第11期4665-4682,共18页Zhenwei Su Hamz oucetta Jiahui Shao Jinling Huang Ran Wang Aining Shen Wei He Zhi Ping Xu Lingxiao Zhang 
European Union's Research and Innovation Program under the Marie Skłodowska-Curie grant agreement(No.101064861);National Natural Science Foundation of China(Nos.32101123,82073782 and 82241002);Guangdong Basic and Applied Basic Research Foundation(No.2022A1515110109,China);Natural Science Foundation of Ningbo(No.2022J273,China).
Aluminum adjuvants(Alum),approved by the US Food and Drug Administration,have been extensively used in vaccines containing recombinant antigens,subunits of pathogens,or toxins for almost a century.While Alums typicall...
关键词：Aluminum adjuvants Layered double hydroxide Nano-aluminum adjuvants Cancer immunotherapy T cell immunity IMMUNOMODULATORY Immunogenic cell death Metal cations 
Adverse drug reactions of first-line antitubercular drugs:A retrospective study on characteristics,management,factors,and impacts
《Asian Pacific Journal of Tropical Medicine》2024年第10期456-464,共9页Ai Ling Oh Mohd Makmor-Bakry Farida Islahudin Chuo Yew Ting Swee Kim Chan Siew Teck Tie 
Objective:To elucidate the characteristics,management strategies,risk factors,and clinical impacts associated with adverse drug reactions(ADRs)induced by first-line antitubercular drugs to enhance tuberculosis(TB)mana...
关键词：Adverse events Cutaneous reactions HEPATOTOXICITY Gastrointestinal disturbances Risk factors TUBERCULOSIS 
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer
《Chinese Medical Journal》2024年第18期2213-2222,共10页Tao Jiang Jian Chen Haowei Wang Fengying Wu Xiaoxia Chen Chunxia Su Haiping Zhang Fei Zhou Ying Yang Jiao Zhang Huaibo Sun Henghui Zhang Caicun Zhou Shengxiang Ren 
supported by grants from the National Natural Science Foundation of China(Nos.82102859,82172869,82141101,82272875,and 12126605);the Shanghai Rising-Star Program(Nos.23QA1408000 and 22QA1407800);the Shanghai"Rising Stars of Medical Talent"Youth Development Program Youth Medical Talents—Specialist Program,the Original Exploration Project of Shanghai Natural Science Foundation(No.23ZR1480600);the Health and Family Planning Commission of Shanghai Municipality(No.20224Y0067)
Background:Programmed death 1(PD-1)blockade plus chemotherapy has become the new first-line standard of care for patients with advanced non-small-cell lung cancer(NSCLC).Yet not all NSCLC patients benefit from this re...
关键词：Non-small-cell lung cancer(NSCLC) Programmed death 1(PD-1)blockade Gene panel Prediction BIOMARKER 
First-line penpulimab(an anti-PD1 antibody)and anlotinib(an angiogenesis inhibitor)with nab-paclitaxel/gemcitabine(PAAG)in metastatic pancreatic cancer:a prospective,multicentre,biomolecular exploratory,phase II trial被引量：5
《Signal Transduction and Targeted Therapy》2024年第7期2960-2969,共10页Huizi Sha Fan Tong Jiayao Ni Yi Sun Yahui Zhu Liang Qi Xiaoqin Li Wei Li Yan Yang Qing Gu Xing Zhang Xiaoxuan Wang Chan Zhu Dongsheng Chen Baorui Liu Juan Du 
National Key Research and Development Program of China(2020YFA0713804);the National Natural Science Foundation of China(82272811);Jiangsu Province Key Research and Development Program(BE2023654);Nanjing Jiangbei New Area Key Research and Development Program,Special Fund of Health Science and Technology Development of Nanjing(YKK20080);Fundings for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University(2023-LCYJ-PY-29).
Metastatic pancreatic cancer(mPC)has a dismal prognosis.Herein,we conducted a prospective,multicentre,single-arm,phase II trial evaluating the efficacy and safety of penpulimab and anlotinib in combination with nab-pa...
关键词：CA724 PROSPECTIVE centre 
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic,gastrointestinal,and urinary bladder carcinomas:Recent concept
《World Journal of Hepatology》2024年第4期490-493,共4页Mohamed Wishahi 
Cancer immunotherapy is administered for first-line,second-line,neoadjuvant,or adjuvant treatment of advanced,metastatic,and recurrent cancer in the liver,gastrointestinal tract,and genitourinary tract,and other solid...
关键词：Programmed cell death protein-ligand 1 Erdafitinib Liver cancer Fibroblast growth factor receptor inhibitors Checkpoint inhibitors Bladder cancer Metastases 
First-line camrelizumab(a PD-1 inhibitor)plus apatinib(an VEGFR-2 inhibitor)and chemotherapy for advanced gastric cancer(SPACE):a phase 1 study被引量：2
《Signal Transduction and Targeted Therapy》2024年第4期1760-1767,共8页Xiaofeng Chen Hao Xu Xiaobing Chen Tongpeng Xu Yitong Tian Deqiang Wang Fen Guo Kangxin Wang Guangfu Jin Xiao Li Rong Wang Fengyuan Li Yongbin Ding Jie Tang Yueyu Fang Jing Zhao Liang Liu Ling Ma Lijuan Meng Zhiguo Hou Rongrong Zheng Yang Liu Ni Guan Bei Zhang Shuang Tong Shiqing Chen Xing Li Yongqian Shu 
funded by the Jiangsu Province 333 High Level Talents Project,the Beijing Xisike Clinical Oncology Research Foundation (Y-HR2019-0367);the National Natural Science Foundation of China (82102981);the Pukou District Social Cause Science and Technology Development Project in 2020 (S2020-21);the Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing Pukou Central Hospital)General Project of Science and Technology Development Fund in 2021 (KJ2021-22);the Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing Pukou Central Hospital)Major Project of Science and Technology Development Fund in 2021 (KJ2021-1);Jiangsu Hengrui Pharmaceuticals.
Patients with advanced gastric cancer typically face a grim prognosis.This phase 1a(dose escalation)and phase 1b(dose expansion)study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemo...
关键词：REGIMEN cancer doses 
The real-world study of the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer in China被引量：1
《Journal of Pancreatology》2024年第1期1-9,共9页Jiujie Cui Qihan Fu Xiaobing Chen Yanling Wang Qi Li Feng Wang Zhihua Li Guanghai Dai Yusheng Wang Hongmei Zhang Houjie Liang Jun Zhou Liu Yang Fenghua Wang Leizhen Zheng Xiaofeng Chen Ping Gong Jiang Liu Ying Yuan Lin Wang Yuejuan Cheng Jun Zhang Yuhong Zhou Weijian Guo Xianbao Zhan Zhengyun Zou Da Li Shan Zeng Enxiao Li Zhiwei Li Zan Teng Dan Cao Jie Kan Jianping Xiong Ming Quan Jiayu Yao Haiyan Yang Liwei Wang 
funded by the National Natural Science Foundation of China(Grant nos.81874048,82171824,82272906);Shanghai Municipal Commission of Health and Family Planning Grant 2018ZHYL0223;Shanghai Municipal Education Commission—Gao Feng Clinical Medicine Grant Support(Grant no.20161312);Scientific and Technological Innovation Project of Science and Technology Commission of Shanghai Municipality(Grant no.21JC1404300);Clinical Research Plan of SHDC(Grant no.SHDC2020CR1035B);Innovation Group Project of Shanghai Municipal Health Commission(Grant no.2019CXJQ03);National Key R&D Program of China(Grant no.2019YFC1315900);Project from CSCO Clinical Oncology Research Foundation(Grant no.Y-2019AZZD-0513);the Innovative Research Team of High-Level Local Universities in Shanghai(Grant no.SHSMU-ZDCX20210802).
Objective:Real-world diagnostic and treatment data for pancreatic cancer in China are lacking.As such,the present study investigated the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer(i...
关键词：Advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study 
全选清除导出
共11页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部